Glioblastoma (GBM) is the most common and the most lethal brain cancer. The challenges inherent in developing effective GBM therapeutics include resistance to standard treatments such as radiation and chemotherapy, limited drug delivery into the tumor due to the Blood-Brain-Barrier (BBB), genetic and molecular heterogeneity, and a subpopulation of stem-like GBM cells (GSCs). Here, we propose a novel strategy that may overcome the above hurdles. Our recent studies have discovered that dopamine receptor subtype 2 (DRD2), a key receptor for dopamine signaling in the brain, promoted GBM growth and survival. Mechanistically, oncogenic DRD2 signaling in GBM activates c-MET receptor, a key regulator for cancer stem phenotype and GBM therapeutic resistance, via direct interaction between DRD2 and c-MET. Importantly, DRD2 inhibition via an FDA-approved DRD2 antagonist, which can freely pass the BBB, potently inactivated oncogenic signaling pathways, diminished clonogenic growth of GSCs, and impeded GBM growth. Based on these findings, we propose three Aims to validate the DRD2 targeting as new concept for the treatment of human GBM: 1) The mechanistic Aim will explore how the DRD2 targeting leads to tumor cell death and how inactivation of this axis can be reliably achieved in GBM. 2) The stratification Aim will identify disease subtypes and groups of patients that may be most responsive to the DRD2 targeting based on our finding that a subset of GBM tumors produces dopamine and these tumors are more addicted to oncogenic DRD2 signaling. 3) The goal of therapeutic Aim is the development and preclinical validation of DRD2 antagonists using mouse avatars bearing patient-derived GBM tumors.

Public Health Relevance

Glioblastoma (GBM) is the most common and most lethal primary brain tumor. Median survival of GBM patients is only 15 months despite maximal surgical resection, radiation, and temozolomide chemotherapy. Recent approaches with molecularly targeted agents have been disappointing, with no significant impact on overall survival. The challenges inherent in developing effective GBM treatments include resistance to standard treatments, invasive tumor growth, and the tumor's genetic complexity and molecular adaptability. This proposal aims to establish a novel and effective therapeutic approach based on neurotransmitter- mediated signaling in GBM.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA223370-03
Application #
10062485
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Chen, Weiwei
Project Start
2018-12-06
Project End
2023-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
3
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Cleveland Clinic Lerner
Department
Other Basic Sciences
Type
Schools of Medicine
DUNS #
135781701
City
Cleveland
State
OH
Country
United States
Zip Code
44195